Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 176 entries
Sorted by: Best Match Show Resources per page
Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56.

Frontiers in immunology

Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J, Booth C, Buchbinder D, Burns SO, Chatila TA, Chou J, Daza-Cajigal V, Ott de Bruin LM, de la Morena M, Di Matteo G, Finocchi A, Geha R, Goyal RK, Hayward A, Holland S, Huang CH, Kanariou MG, King A, Kaplan B, Kleva A, Kuijpers TW, Lee BW, Lougaris V, Massaad M, Meyts I, Morsheimer M, Neven B, Pai SY, Parvaneh N, Plebani A, Prockop S, Reisli I, Soh JY, Somech R, Torgerson TR, Kim YJ, Walter JE, Gennery AR, Keles S, Manis JP, Marcenaro E, Moretta A, Parolini S, Notarangelo LD.
PMID: 28769923
Front Immunol. 2017 Jul 17;8:798. doi: 10.3389/fimmu.2017.00798. eCollection 2017.

Mutations of the recombinase-activating genes 1 and 2 (

Cite
Dobbs K, Tabellini G, Calzoni E, et al. Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56. Front Immunol. 2017;8:798doi: 10.3389/fimmu.2017.00798.
Dobbs, K., Tabellini, G., Calzoni, E., Patrizi, O., Martinez, P., Giliani, S. C., Moratto, D., Al-Herz, W., Cancrini, C., Cowan, M., Bleesing, J., Booth, C., Buchbinder, D., Burns, S. O., Chatila, T. A., Chou, J., Daza-Cajigal, V., Ott de Bruin, L. M., de la Morena, M., Di Matteo, G., Finocchi, A., Geha, R., Goyal, R. K., Hayward, A., Holland, S., Huang, C. H., Kanariou, M. G., King, A., Kaplan, B., Kleva, A., Kuijpers, T. W., Lee, B. W., Lougaris, V., Massaad, M., Meyts, I., Morsheimer, M., Neven, B., Pai, S. Y., Parvaneh, N., Plebani, A., Prockop, S., Reisli, I., Soh, J. Y., Somech, R., Torgerson, T. R., Kim, Y. J., Walter, J. E., Gennery, A. R., Keles, S., Manis, J. P., Marcenaro, E., Moretta, A., Parolini, S., & Notarangelo, L. D. (2017). Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56. Frontiers in immunology, 8798. https://doi.org/10.3389/fimmu.2017.00798
Dobbs, Kerry, et al. "Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56." Frontiers in immunology vol. 8 (2017): 798. doi: https://doi.org/10.3389/fimmu.2017.00798
Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J, Booth C, Buchbinder D, Burns SO, Chatila TA, Chou J, Daza-Cajigal V, Ott de Bruin LM, de la Morena M, Di Matteo G, Finocchi A, Geha R, Goyal RK, Hayward A, Holland S, Huang CH, Kanariou MG, King A, Kaplan B, Kleva A, Kuijpers TW, Lee BW, Lougaris V, Massaad M, Meyts I, Morsheimer M, Neven B, Pai SY, Parvaneh N, Plebani A, Prockop S, Reisli I, Soh JY, Somech R, Torgerson TR, Kim YJ, Walter JE, Gennery AR, Keles S, Manis JP, Marcenaro E, Moretta A, Parolini S, Notarangelo LD. Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56. Front Immunol. 2017 Jul 17;8:798. doi: 10.3389/fimmu.2017.00798. eCollection 2017. PMID: 28769923; PMCID: PMC5511964.
Copy Download .nbib Format: NLM
What Does Personality Mean in the Context of Mental Health? A Topic Modeling Approach Based on Abstracts Published in Pubmed Over the Last 5 Years.

Frontiers in psychiatry

Sperandeo R, Messina G, Iennaco D, Sessa F, Russo V, Polito R, Monda V, Monda M, Messina A, Mosca LL, Mosca L, Dell'Orco S, Moretto E, Gigante E, Chiacchio A, Scognamiglio C, Carotenuto M, Maldonato NM.
PMID: 31998157
Front Psychiatry. 2020 Jan 09;10:938. doi: 10.3389/fpsyt.2019.00938. eCollection 2019.

Personality disorders (PDs) are one of the major problems for the organization of public health systems. Deepening the link between personality traits and psychopathological drifts, it seems increasingly essential for the often dramatic repercussions that PDs have on social...

Cite
Sperandeo R, Messina G, Iennaco D, et al. What Does Personality Mean in the Context of Mental Health? A Topic Modeling Approach Based on Abstracts Published in Pubmed Over the Last 5 Years. Front Psychiatry. 2020;10:938doi: 10.3389/fpsyt.2019.00938.
Sperandeo, R., Messina, G., Iennaco, D., Sessa, F., Russo, V., Polito, R., Monda, V., Monda, M., Messina, A., Mosca, L. L., Mosca, L., Dell'Orco, S., Moretto, E., Gigante, E., Chiacchio, A., Scognamiglio, C., Carotenuto, M., & Maldonato, N. M. (2019). What Does Personality Mean in the Context of Mental Health? A Topic Modeling Approach Based on Abstracts Published in Pubmed Over the Last 5 Years. Frontiers in psychiatry, 10938. https://doi.org/10.3389/fpsyt.2019.00938
Sperandeo, Raffaele, et al. "What Does Personality Mean in the Context of Mental Health? A Topic Modeling Approach Based on Abstracts Published in Pubmed Over the Last 5 Years." Frontiers in psychiatry vol. 10 (2019): 938. doi: https://doi.org/10.3389/fpsyt.2019.00938
Sperandeo R, Messina G, Iennaco D, Sessa F, Russo V, Polito R, Monda V, Monda M, Messina A, Mosca LL, Mosca L, Dell'Orco S, Moretto E, Gigante E, Chiacchio A, Scognamiglio C, Carotenuto M, Maldonato NM. What Does Personality Mean in the Context of Mental Health? A Topic Modeling Approach Based on Abstracts Published in Pubmed Over the Last 5 Years. Front Psychiatry. 2020 Jan 09;10:938. doi: 10.3389/fpsyt.2019.00938. eCollection 2019. PMID: 31998157; PMCID: PMC6962292.
Copy Download .nbib Format: NLM
Beyond the Third Dimension: Combined Functional and Anatomical Assessment of Anomalous Origin of Coronary Arteries.

Seminars in thoracic and cardiovascular surgery

Buratto E, Konstantinov IE.
PMID: 34271091
Semin Thorac Cardiovasc Surg. 2021 Jul 13; doi: 10.1053/j.semtcvs.2021.07.004. Epub 2021 Jul 13.

No abstract available.

Cite
Buratto E, Konstantinov IE. Beyond the Third Dimension: Combined Functional and Anatomical Assessment of Anomalous Origin of Coronary Arteries. Semin Thorac Cardiovasc Surg. 2021;doi: 10.1053/j.semtcvs.2021.07.004.
Buratto, E., & Konstantinov, I. E. (2021). Beyond the Third Dimension: Combined Functional and Anatomical Assessment of Anomalous Origin of Coronary Arteries. Seminars in thoracic and cardiovascular surgery, . https://doi.org/10.1053/j.semtcvs.2021.07.004
Buratto, Edward, and Konstantinov, Igor E. "Beyond the Third Dimension: Combined Functional and Anatomical Assessment of Anomalous Origin of Coronary Arteries." Seminars in thoracic and cardiovascular surgery vol. (2021). doi: https://doi.org/10.1053/j.semtcvs.2021.07.004
Buratto E, Konstantinov IE. Beyond the Third Dimension: Combined Functional and Anatomical Assessment of Anomalous Origin of Coronary Arteries. Semin Thorac Cardiovasc Surg. 2021 Jul 13; doi: 10.1053/j.semtcvs.2021.07.004. Epub 2021 Jul 13. PMID: 34271091.
Copy Download .nbib Format: NLM
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Antonetti P, Fargnoli MC, Porzio G, Salvatore L, Filippi R, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Dell'Aquila E, Lombardi P, Keränen SR, Depetris I, Giampieri R, Morelli C, De Tursi M, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Cortellini A, Pensieri MV, Ficorella C, Ferri C, Parisi A.
PMID: 34779921
Support Care Cancer. 2021 Nov 15; doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15.

BACKGROUND: Skin toxicity in patients affected by metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor (EGFR) inhibitors is well known. However, ad hoc ESMO guidelines have only recently been published.AIM AND METHODS: To describe the management (pre-emptive...

Cite
Antonetti P, Fargnoli MC, Porzio G, et al. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. Support Care Cancer. 2021;doi: 10.1007/s00520-021-06652-5.
Antonetti, P., Fargnoli, M. C., Porzio, G., Salvatore, L., Filippi, R., Ghidini, M., Nigro, O., Gelsomino, F., Zurlo, I. V., Dell'Aquila, E., Lombardi, P., Keränen, S. R., Depetris, I., Giampieri, R., Morelli, C., De Tursi, M., Di Pietro, F. R., Zanaletti, N., Vitale, P., Garajova, I., Spinelli, G. P., Zoratto, F., Roberto, M., Petrillo, A., Aimar, G., Cortellini, A., Pensieri, M. V., Ficorella, C., Ferri, C., & Parisi, A. (2021). A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, . https://doi.org/10.1007/s00520-021-06652-5
Antonetti, Paolo, et al. "A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. (2021). doi: https://doi.org/10.1007/s00520-021-06652-5
Antonetti P, Fargnoli MC, Porzio G, Salvatore L, Filippi R, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Dell'Aquila E, Lombardi P, Keränen SR, Depetris I, Giampieri R, Morelli C, De Tursi M, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Cortellini A, Pensieri MV, Ficorella C, Ferri C, Parisi A. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. Support Care Cancer. 2021 Nov 15; doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15. PMID: 34779921.
Copy Download .nbib Format: NLM
Corrigendum to "Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family" [Redox Biol. 37 (2020 Sep 6) 101705-101721].

Redox biology

Peruzzo R, Mattarei A, Azzolini M, Becker-Flegler KA, Romio M, Rigoni G, Carrer A, Biasutto L, Parrasia S, Kadow S, Managò A, Urbani A, Rossa A, Semenzato G, Soriano ME, Trentin L, Ahmad S, Edwards M, Gulbins E, Paradisi C, Zoratti M, Leanza L, Szabò I.
PMID: 34210643
Redox Biol. 2021 Sep;45:102036. doi: 10.1016/j.redox.2021.102036. Epub 2021 Jun 29.

No abstract available.

Cite
Peruzzo R, Mattarei A, Azzolini M, et al. Corrigendum to "Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family" [Redox Biol. 37 (2020 Sep 6) 101705-101721]. Redox Biol. 2021;45:102036doi: 10.1016/j.redox.2021.102036.
Peruzzo, R., Mattarei, A., Azzolini, M., Becker-Flegler, K. A., Romio, M., Rigoni, G., Carrer, A., Biasutto, L., Parrasia, S., Kadow, S., Managò, A., Urbani, A., Rossa, A., Semenzato, G., Soriano, M. E., Trentin, L., Ahmad, S., Edwards, M., Gulbins, E., Paradisi, C., Zoratti, M., Leanza, L., & Szabò, I. (2021). Corrigendum to "Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family" [Redox Biol. 37 (2020 Sep 6) 101705-101721]. Redox biology, 45102036. https://doi.org/10.1016/j.redox.2021.102036
Peruzzo, Roberta, et al. "Corrigendum to "Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family" [Redox Biol. 37 (2020 Sep 6) 101705-101721]." Redox biology vol. 45 (2021): 102036. doi: https://doi.org/10.1016/j.redox.2021.102036
Peruzzo R, Mattarei A, Azzolini M, Becker-Flegler KA, Romio M, Rigoni G, Carrer A, Biasutto L, Parrasia S, Kadow S, Managò A, Urbani A, Rossa A, Semenzato G, Soriano ME, Trentin L, Ahmad S, Edwards M, Gulbins E, Paradisi C, Zoratti M, Leanza L, Szabò I. Corrigendum to "Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family" [Redox Biol. 37 (2020 Sep 6) 101705-101721]. Redox Biol. 2021 Sep;45:102036. doi: 10.1016/j.redox.2021.102036. Epub 2021 Jun 29. PMID: 34210643; PMCID: PMC8270548.
Copy Download .nbib Format: NLM
Research Techniques Made Simple: Lipidomic Analysis in Skin Research.

The Journal of investigative dermatology

Sochorová M, Vávrová K, Fedorova M, Ni Z, Slenter D, Kutmon M, Willighagen EL, Letsiou S, Töröcsik D, Marchetti-Deschmann M, Zoratto S, Kremslehner C, Gruber F.
PMID: 34924150
J Invest Dermatol. 2022 Jan;142(1):4-11.e1. doi: 10.1016/j.jid.2021.09.017.

Although lipids are crucial molecules for cell structure, metabolism, and signaling in most organs, they have additional specific functions in the skin. Lipids are required for the maintenance and regulation of the epidermal barrier, physical properties of the skin,...

Cite
Sochorová M, Vávrová K, Fedorova M, et al. Research Techniques Made Simple: Lipidomic Analysis in Skin Research. J Invest Dermatol. 2022;142(1):4-11.e1doi: 10.1016/j.jid.2021.09.017.
Sochorová, M., Vávrová, K., Fedorova, M., Ni, Z., Slenter, D., Kutmon, M., Willighagen, E. L., Letsiou, S., Töröcsik, D., Marchetti-Deschmann, M., Zoratto, S., Kremslehner, C., & Gruber, F. (2022). Research Techniques Made Simple: Lipidomic Analysis in Skin Research. The Journal of investigative dermatology, 142(1), 4-11.e1. https://doi.org/10.1016/j.jid.2021.09.017
Sochorová, Michaela, et al. "Research Techniques Made Simple: Lipidomic Analysis in Skin Research." The Journal of investigative dermatology vol. 142,1 (2022): 4-11.e1. doi: https://doi.org/10.1016/j.jid.2021.09.017
Sochorová M, Vávrová K, Fedorova M, Ni Z, Slenter D, Kutmon M, Willighagen EL, Letsiou S, Töröcsik D, Marchetti-Deschmann M, Zoratto S, Kremslehner C, Gruber F. Research Techniques Made Simple: Lipidomic Analysis in Skin Research. J Invest Dermatol. 2022 Jan;142(1):4-11.e1. doi: 10.1016/j.jid.2021.09.017. PMID: 34924150.
Copy Download .nbib Format: NLM
COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males.

Viruses

Fonseca W, Asai N, Yagi K, Malinczak CA, Savickas G, Johnson CC, Murray S, Zoratti EM, Lukacs NW, Li J, Schuler Iv CF.
PMID: 34960684
Viruses. 2021 Dec 02;13(12). doi: 10.3390/v13122415.

BACKGROUND AND OBJECTIVES: African Americans and males have elevated risks of infection, hospitalization, and death from SARS-CoV-2 in comparison with other populations. We report immune responses and renal injury markers in African American male patients hospitalized for COVID-19.METHODS: This...

Cite
Fonseca W, Asai N, Yagi K, et al. COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males. Viruses. 2021;13(12)doi: 10.3390/v13122415.
Fonseca, W., Asai, N., Yagi, K., Malinczak, C. A., Savickas, G., Johnson, C. C., Murray, S., Zoratti, E. M., Lukacs, N. W., Li, J., & Schuler Iv, C. F. (2021). COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males. Viruses, 13(12), . https://doi.org/10.3390/v13122415
Fonseca, Wendy, et al. "COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males." Viruses vol. 13,12 (2021). doi: https://doi.org/10.3390/v13122415
Fonseca W, Asai N, Yagi K, Malinczak CA, Savickas G, Johnson CC, Murray S, Zoratti EM, Lukacs NW, Li J, Schuler Iv CF. COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males. Viruses. 2021 Dec 02;13(12). doi: 10.3390/v13122415. PMID: 34960684.
Copy Download .nbib Format: NLM
Degenerative Cervical Disorder-Stand-alone Cage Versus Cage and Cervical Plate: A Systematic Review.

Global spine journal

Boer LFR, Zorzetto E, Yeh F, Wajchenberg M, Martins DE.
PMID: 32875874
Global Spine J. 2021 Mar;11(2):249-255. doi: 10.1177/2192568220906173. Epub 2020 Mar 05.

STUDY DESIGN: Systematic review.OBJECTIVES: The objective of this study was to compare clinical and radiological outcomes following discectomy and anterior cervical fusion for the treatment of cervical degenerative disorder performed with stand-alone cages and anterior cervical plates.METHODS: Electronic searches...

Cite
Boer LFR, Zorzetto E, Yeh F, et al. Degenerative Cervical Disorder-Stand-alone Cage Versus Cage and Cervical Plate: A Systematic Review. Global Spine J. 2020;11(2):249-255doi: 10.1177/2192568220906173.
Boer, L. F. R., Zorzetto, E., Yeh, F., Wajchenberg, M., & Martins, D. E. (2021). Degenerative Cervical Disorder-Stand-alone Cage Versus Cage and Cervical Plate: A Systematic Review. Global spine journal, 11(2), 249-255. https://doi.org/10.1177/2192568220906173
Boer, Luis Fernando Ricci, et al. "Degenerative Cervical Disorder-Stand-alone Cage Versus Cage and Cervical Plate: A Systematic Review." Global spine journal vol. 11,2 (2021): 249-255. doi: https://doi.org/10.1177/2192568220906173
Boer LFR, Zorzetto E, Yeh F, Wajchenberg M, Martins DE. Degenerative Cervical Disorder-Stand-alone Cage Versus Cage and Cervical Plate: A Systematic Review. Global Spine J. 2021 Mar;11(2):249-255. doi: 10.1177/2192568220906173. Epub 2020 Mar 05. PMID: 32875874; PMCID: PMC7882813.
Copy Download .nbib Format: NLM
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis.

EClinicalMedicine

Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, Ford N, Thorlund K, Anis PAH, Karim ME, Mofenson L, Zash R, Calmy A, Kredo T, Bansback N.
PMID: 33294805
EClinicalMedicine. 2020 Oct 16;28:100573. doi: 10.1016/j.eclinm.2020.100573. eCollection 2020 Nov.

BACKGROUND: To inform World Health Organization (WHO) global guidelines, we updated and expanded the evidence base to assess the comparative efficacy, tolerability, and safety of first-line antiretroviral therapy (ART) regimens.METHODS: We searched Embase, Medline and CENTRAL on 28 February...

Cite
Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine. 2020;28:100573doi: 10.1016/j.eclinm.2020.100573.
Kanters, S., Vitoria, M., Zoratti, M., Doherty, M., Penazzato, M., Rangaraj, A., Ford, N., Thorlund, K., Anis, P. A. H., Karim, M. E., Mofenson, L., Zash, R., Calmy, A., Kredo, T., & Bansback, N. (2020). Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine, 28100573. https://doi.org/10.1016/j.eclinm.2020.100573
Kanters, Steve, et al. "Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis." EClinicalMedicine vol. 28 (2020): 100573. doi: https://doi.org/10.1016/j.eclinm.2020.100573
Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, Ford N, Thorlund K, Anis PAH, Karim ME, Mofenson L, Zash R, Calmy A, Kredo T, Bansback N. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine. 2020 Oct 16;28:100573. doi: 10.1016/j.eclinm.2020.100573. eCollection 2020 Nov. PMID: 33294805; PMCID: PMC7700905.
Copy Download .nbib Format: NLM
The role of metabolic adaptation to nutrient stress in pancreatic cancer.

Cell stress

Derle A, De Santis MC, Gozzelino L, Ratto E, Martini M.
PMID: 31225458
Cell Stress. 2018 Nov 15;2(12):332-339. doi: 10.15698/cst2018.12.166.

Pancreatic cancer is the fourth most common cause of cancer-related mortality, with a dismal prognosis that has changed little over the past few decades. Despite extensive efforts in understanding the oncogenetics of this pathology, pancreatic cancer remained largely elusive....

Cite
Derle A, De Santis MC, Gozzelino L, et al. The role of metabolic adaptation to nutrient stress in pancreatic cancer. Cell Stress. 2018;2(12):332-339doi: 10.15698/cst2018.12.166.
Derle, A., De Santis, M. C., Gozzelino, L., Ratto, E., & Martini, M. (2018). The role of metabolic adaptation to nutrient stress in pancreatic cancer. Cell stress, 2(12), 332-339. https://doi.org/10.15698/cst2018.12.166
Derle, Abhishek, et al. "The role of metabolic adaptation to nutrient stress in pancreatic cancer." Cell stress vol. 2,12 (2018): 332-339. doi: https://doi.org/10.15698/cst2018.12.166
Derle A, De Santis MC, Gozzelino L, Ratto E, Martini M. The role of metabolic adaptation to nutrient stress in pancreatic cancer. Cell Stress. 2018 Nov 15;2(12):332-339. doi: 10.15698/cst2018.12.166. PMID: 31225458; PMCID: PMC6551672.
Copy Download .nbib Format: NLM
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.

Journal for immunotherapy of cancer

Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ.
PMID: 33827906
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2021-002421.

BACKGROUND: Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether...

Cite
Cortellini A, Di Maio M, Nigro O, et al. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021;9(4)doi: 10.1136/jitc-2021-002421.
Cortellini, A., Di Maio, M., Nigro, O., Leonetti, A., Cortinovis, D. L., Aerts, J. G., Guaitoli, G., Barbieri, F., Giusti, R., Ferrara, M. G., Bria, E., D'Argento, E., Grossi, F., Rijavec, E., Guida, A., Berardi, R., Torniai, M., Sforza, V., Genova, C., Mazzoni, F., Garassino, M. C., De Toma, A., Signorelli, D., Gelibter, A., Siringo, M., Marchetti, P., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Della Gravara, L., Inno, A., Michele, T., Grassadonia, A., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Santini, D., Citarella, F., Russano, M., Cantini, L., Tuzi, A., Bordi, P., Minuti, G., Landi, L., Ricciardi, S., Migliorino, M. R., Passiglia, F., Bironzo, P., Metro, G., Adamo, V., Russo, A., Spinelli, G. P., Banna, G. L., Friedlaender, A., Addeo, A., Cannita, K., Ficorella, C., Porzio, G., & Pinato, D. J. (2021). Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. Journal for immunotherapy of cancer, 9(4), . https://doi.org/10.1136/jitc-2021-002421
Cortellini, Alessio, et al. "Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy." Journal for immunotherapy of cancer vol. 9,4 (2021). doi: https://doi.org/10.1136/jitc-2021-002421
Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2021-002421. PMID: 33827906; PMCID: PMC8031700.
Copy Download .nbib Format: NLM
N-terminal VP1 Truncations Favor .

Vaccines

Pogan R, Weiss VU, Bond K, Dülfer J, Krisp C, Lyktey N, Müller-Guhl J, Zoratto S, Allmaier G, Jarrold MF, Muñoz-Fontela C, Schlüter H, Uetrecht C.
PMID: 33374273
Vaccines (Basel). 2020 Dec 24;9(1). doi: 10.3390/vaccines9010008.

Noroviruses cause immense sporadic gastroenteritis outbreaks worldwide. Emerging genotypes, which are divided based on the sequence of the major capsid protein VP1, further enhance this public threat. Self-assembling properties of the human norovirus major capsid protein VP1 are crucial...

Cite
Pogan R, Weiss VU, Bond K, et al. N-terminal VP1 Truncations Favor . Vaccines (Basel). 2020;9(1)doi: 10.3390/vaccines9010008.
Pogan, R., Weiss, V. U., Bond, K., Dülfer, J., Krisp, C., Lyktey, N., Müller-Guhl, J., Zoratto, S., Allmaier, G., Jarrold, M. F., Muñoz-Fontela, C., Schlüter, H., & Uetrecht, C. (2020). N-terminal VP1 Truncations Favor . Vaccines, 9(1), . https://doi.org/10.3390/vaccines9010008
Pogan, Ronja, et al. "N-terminal VP1 Truncations Favor ." Vaccines vol. 9,1 (2020). doi: https://doi.org/10.3390/vaccines9010008
Pogan R, Weiss VU, Bond K, Dülfer J, Krisp C, Lyktey N, Müller-Guhl J, Zoratto S, Allmaier G, Jarrold MF, Muñoz-Fontela C, Schlüter H, Uetrecht C. N-terminal VP1 Truncations Favor . Vaccines (Basel). 2020 Dec 24;9(1). doi: 10.3390/vaccines9010008. PMID: 33374273; PMCID: PMC7824077.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 176 entries